Status:
RECRUITING
Study for Characterisation of Predictive Parameters of Clonal Evolution in Subjects With GATA2 Germline Mutation
Lead Sponsor:
Institut Claudius Regaud
Conditions:
GATA2 Gene Mutation
Eligibility:
All Genders
Phase:
NA
Brief Summary
This trial is a translational, open-label, multi-site, retrospective and prospective cohort study of 250 patients aiming to characterize predictive parameters of clonal evolution in a population of su...
Eligibility Criteria
Inclusion
- All subject, at any age, with a germline GATA2 mutation.
- Patient followed in the center within a standard of care procedure or clinical trial.
- Signed written informed consent. For minor patients: patient assent and legal guardian(s) written informed consent obtained before inclusion in the study and prior performance of any study-related procedure.
- For French patients: patient affiliated to a Social Health Insurance.
Exclusion
- GATA2 somatic mutation.
- Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
- Person who has forfeited his/her freedom by administrative or legal award or who is under legal protection, with the exception of persons under curatorship who may be included in the study.
Key Trial Info
Start Date :
December 7 2023
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2033
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05983991
Start Date
December 7 2023
End Date
December 1 2033
Last Update
December 26 2025
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France
2
CHU Bordeaux
Bordeaux, France
3
CHU Estaing
Clermont-Ferrand, France
4
CHU Dijon
Dijon, France